Drug Trial Radar · NCT00002651
SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Apr 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,040
Actual
Start
May 1995
Primary completion
Jun 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; European Organisation for Research and Treatment of Cancer - EORTC
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy may be effective treatment for prostate cancer. It is not yet known which regimen of hormone therapy is most effective for stage IV prostate cancer. PURPOSE: This randomized phase III trial is studying two different regimens of hormone therapy and comparing how well they work in treating men with stage IV prostate cancer.
Conditions
- Prostate Cancer
Interventions
bicalutamideDrug
Given orally
goserelin acetateDrug
Given subcutaneously
clinical observationOther
Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Up to 15 years
- Physical Functioning as Measured by the SF-36Time frame: 3 months
- Emotional Functioning as Measured by the SF-36 Mental Health InventoryTime frame: 3 months
- Erectile DysfunctionTime frame: 3 months
- High LibidoTime frame: 3 months
- VitalityTime frame: 3 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Tom Baker Cancer Centre - Calgary
Calgary, Alberta, Canada
Cross Cancer Institute at University of Alberta
Edmonton, Alberta, Canada
University of British Columbia
Vancouver, British Columbia, Canada
Nova Scotia Cancer Centre
Halifax, Nova Scotia, Canada
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, Canada
London Regional Cancer Program at London Health Sciences Centre
London, Ontario, Canada
Ottawa Hospital Regional Cancer Centre - General Campus
Ottawa, Ontario, Canada
Odette Cancer Centre at Sunnybrook
Toronto, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
Hopital Notre-Dame du CHUM
Montreal, Quebec, Canada
McGill Cancer Centre at McGill University
Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Quebec
Québec, Quebec, Canada
CHUS-Hopital Fleurimont
Sherbrooke, Quebec, Canada
Saskatoon Cancer Centre at the University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.